StockData
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. (LYEL) stock

LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.67−0.98 (-6.69%)

Close on Nov 17, 2026Market cap $334.99MP/E –Yield –

Lyell Immunopharma cash

Cash and short-term investments held at the end of each period.

Lyell Immunopharma's cash was $204.10M at Jun 30, 2026. For fiscal 2025 it was $247.22M, down 33.6% from the year before. The highest annual figure on record is $640.43M in fiscal 2022.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$247.22M-33.6%
FY2024Dec 31, 2024$372.22M-31.9%
FY2023Dec 31, 2023$546.22M-14.7%
FY2022Dec 31, 2022$640.43M+4.1%
FY2021Dec 31, 2021$615.26M+0.4%
FY2020Dec 31, 2020$613.09M+522.6%
FY2019Dec 31, 2019$98.47M-24.4%
FY2018Dec 31, 2018$130.28M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$204.10M-26.3%
Q1 FY2026Mar 31, 2026$254.02M-15.7%
Q4 FY2025Dec 31, 2025$247.22M-33.6%
Q3 FY2025Sep 30, 2025$319.62M-27.4%
Q2 FY2025Jun 30, 2025$276.79M-43.6%
Q1 FY2025Mar 31, 2025$301.18M-42.8%
Q4 FY2024Dec 31, 2024$372.22M-31.9%
Q3 FY2024Sep 30, 2024$440.55M-23.4%
Q2 FY2024Jun 30, 2024$491.12M-17.6%
Q1 FY2024Mar 31, 2024$526.30M-14.1%
Q4 FY2023Dec 31, 2023$546.22M-14.7%
Q3 FY2023Sep 30, 2023$575.43M-11.2%
Q2 FY2023Jun 30, 2023$595.75M-9.1%
Q1 FY2023Mar 31, 2023$612.77M-0.2%
Q4 FY2022Dec 31, 2022$640.43M+4.1%
Q3 FY2022Sep 30, 2022$648.13M+4.7%
Q2 FY2022Jun 30, 2022$655.56M-20.5%
Q1 FY2022Mar 31, 2022$613.91M+151.2%
Q4 FY2021Dec 31, 2021$615.26M+0.4%
Q3 FY2021Sep 30, 2021$618.92M+360.5%
Q2 FY2021Jun 30, 2021$824.52M+235.2%
Q1 FY2021Mar 31, 2021$244.37M+148.2%
Q4 FY2020Dec 31, 2020$613.09M+370.6%
Q3 FY2020Sep 30, 2020$134.41M–
Q2 FY2020Jun 30, 2020$245.95M–
Q4 FY2019Dec 31, 2019$98.47M–
Q4 FY2018Dec 31, 2018$130.28M–

More Lyell Immunopharma figures

See a number that looks wrong?